title: What is the Most Cost-Effective Strategy for Treating Chronic Myeloid Leukemia After Imatinib Loses Patent Exclusivity in Europe?
authors.affiliation: University of Chicago, Chicago, IL, USA.
authors.forename: W V
authors.initials: WV
authors.lastname: Padula
authors.affiliation: University of Chicago, Chicago, GA, USA.
authors.forename: R
authors.initials: R
authors.lastname: Conti
authors.affiliation: University of Chicago, Chicago, IL, USA.
authors.forename: R
authors.initials: R
authors.lastname: Larson